Anticoagulants Market By Drug Class (Factor X Inhibitor (NOAC/DOAC) Anticoagulants, Heparin Anticoagulants, Direct Thrombin Inhibitor Anticoagulants, Vitamin K Antagonist Anticoagulants), By Route of Administration, By Indication - Global Market Insights 2021 to 2031
Anticoagulants Market Outlook
The sales of anticoagulant are expected to reach US$ 30 Bn by the end of 2021. As per the study, demand will continue rising, expanding over 2x to be valued at US$ 65 Bn by the end of the 2021-2031 assessment period.
Players are increasingly utilizing internet sales channels to extend their reach while requiring less financial commitment. On the demand side, the rising incidence of heart attacks, owing to patients' unhealthy lifestyle choices, is expected to expand the patient pool for the anticoagulants market over the forecast period.
Key Points Addressed in Anticoagulant Industry Analysis
- Market Estimates and Forecasts (2016-2031)
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Brand Share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Anticoagulants Demand and How to Navigate
- Recommendation on Key Winning Strategies
Anticoagulants Consumption Analysis 2016-2020 Vs Outlook 2021-2031
Sales of anticoagulants expanded at a CAGR of 5% across the historical period ranging from 2016 to 2020. Demand for anticoagulants has increased significantly in emerging nations, owing to the financial assistance provided by central governments to renovate healthcare facilities and improve service quality.
Leading firms are utilizing research and development operations to increase the number of pipeline medicines, recognizing the anticoagulants market's strong growth possibilities. The Global Anticoagulants Market is estimated to be worth US$ 65 Bn by 2031, expanding at an 8.04 % CAGR during the forecast period.
Surging Atrial Fibrillation Cases Spurring Anticoagulants Consumption?
The most common heart arrhythmia is atrial fibrillation. It is projected that 6-12 million individuals in the United States will have this disease by 2050, and 17.9 million people in Europe will have it by 2060. Atrial fibrillation is a substantial risk factor for ischemic stroke, causing a large economic burden as well as morbidity and death.
As per the National Center for Biotechnology Information, during 2017, over 3 million new instances of atrial fibrillation were detected globally. The 2017 estimated incidence rate (403/million inhabitants) was 31% higher than the 1997 corresponding incidence. The global prevalence of atrial fibrillation is 37,574 million instances, and it has grown by 33% in the past two decades.
The biggest burden is observed in nations with a high socio-demographic index; however the most recent growth occurred in countries with a moderate socio-demographic index. According to estimates, the absolute burden of atrial fibrillation may grow by more than 60% by 2050. Hence, all these factors contribute to the market growth during the forecast period.
Avail customized purchase options for your needs
Country Wise Analysis
How do Anticoagulants Growth Prospects Appear in the U.S?
U.S. accounted for the biggest proportion of anticoagulants in 2020, owing to increased knowledge about the therapeutic uses of anticoagulants in disease management and the country's rising obesity prevalence. Furthermore, it has the highest obesity prevalence in the world.
According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017–2018. Obesity in the United States rose from 30.5% to 42.4% between 1999 and 2018. Based on aforementioned trends, the U.S market is expected to surge at a CAGR of 7.5% until 2031.
How big is the Anticoagulants Industry in Japan?
According to the World Bank, a projected 28% of Japan's total population is over 65 in 2020, with that figure predicted to increase to 40% by 2060. As a result, blood thinners such as Xarelto are widely recommended to the elderly for the treatment and prevention of blood clots. A market share worth 45% is expected for the Japanese market.
With an ageing population, demand for anticoagulants is strong, as they require surgical interventions for numerous chronic conditions. Geriatrics are more likely to have diseases such as venous thromboembolism, atrial fibrillation, and knee and hip replacement operations, increasing their risk of forming blood clots and, as a result, heart attacks and strokes.
Why is China an Emerging Market for Anticoagulants?
China is anticipated to expand at the highest rate throughout the projection period, clocking a CAGR exceeding 8% until 2031. High prevalence rate of cardiovascular diseases is spurring surgeries across the East Asian giant, paving way for high usage of anticoagulants.
According to the Lancet, nearly 4 million deaths occur due to CVDs in China annually. In an effort to mitigate the risk and reduce this burden, healthcare practitioners are advocating advanced surgical interventions. However, the risk of embolism arising from such surgeries has also increased, prompting usage of anticoagulants.
Category Wise Insights
Why the Preference for NOAC/DOAC Factor X Inhibitors?
By drug class, NOAC/DOAC factor X inhibitors accounted for over 50% of total anticoagulants demand in 2019. This is attributed to increased NOAC uptake in poorer nations, as well as increased usage of NOACs over warfarin.
Furthermore, NOACs including betrixaban, rivaroxaban, apixaban, dabigatran, and edoxaban are used to treat and prevent atrial fibrillation/myocardial infarction, pulmonary embolism, and deep vein thrombosis (DVT). They possess numerous advantages over warfarin, including minimal dietary restrictions, fast start effect, predictable pharmacokinetic action, less drug and food interaction, and a shorter half-life.
Why are Hospital Pharmacies Primary Anticoagulants Distributors?
Hospital pharmacies are expected to account for 49.2% revenue share. This is because hospitals are the major sites for the diagnosis and treatment of many forms of bleeding problems.
As the volume of surgeries for various chronic conditions increase, episodes of embolisms post-surgery are increasing manifold. As a result, doctors highly recommend use of anticoagulants to prevent further complications in the patient.
An Adaptive Approach to Modern-day Research Needs
The anticoagulants landscape is competitive and fragmented, with numerous significant competitors. As a tool to increase anticoagulant exposure, players in the anticoagulants industry are stepping forward to carry the financial burden of individuals through patient-assistance programmes.
- In August 2020, Bristol-Myers Squibb, in alliance with Pfizer, announced that the U.S District Court upheld their composition of matter (COP) patent (US 6,967,208) and formulation patent (US 9,326,945) covering their Eliquis® Apixaban anticoagulants.
- Likewise, in November 2020, Boehringer Ingelheim received approval from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for the use of Pradaxa® (dabigatran etexilate) for treating venous thromboembolic events and preventing its recurrence in pediatric patients below 18 years
Market size value in 2021
|USD 30 Billion|
Market forecast value in 2031
|USD 65 Billion|
|CAGR of 8.04% from 2021 to 2031|
|Historical Data Available for||2016-2020|
|US$ Mn for Value & ‘000 Units for Volume|
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Available upon Request
Interested to Procure The Data
Key Segments Covered
- Factor X Inhibitor (NOAC/DOAC) Anticoagulants
- Heparin Anticoagulants
- Direct Thrombin Inhibitor Anticoagulants
- Vitamin K Antagonist Anticoagulants
- Anticoagulants for Deep Vein Thrombosis
- Anticoagulants for Pulmonary Embolism
- Anticoagulants for Atrial Fibrillation & Heart Attack
- Anticoagulants for Other Indications
Route of Administration
- Oral Anticoagulants
- Injectable Anticoagulants
- Anticoagulants Sales via Hospital Pharmacies
- Anticoagulants Sales via Retail Pharmacies
- Anticoagulants Sales via Online Pharmacies
- FAQs -
According to Fact.MR, the anticoagulants industry is expected to reach US$ 30 Bn in 2021.
From 2016 to 2020, Fact.MR estimated the market for anticoagulants soared at 5% CAGR
From 2021 to 2031, anticoagulants demand is expected to surge at a CAGR exceeding 8%
Rising prevalence of atrial fibrillation and heart attacks is anticipated to increase uptake of anticoagulants
Demand for anticoagulants in the U.S is expected to surge at a CAGR of 7.5% from 2021 to 2031
Anticoagulants sales are expected to comprise 45% of the revenue share across Japan
China is anticipated to register a growth rate of over 8% across the forthcoming decade
NOAC/DOAC factor X-inhibitors are expected to be highly sought after, capturing 50% of total demand
Hospital pharmacies account for bulk of anticoagulants distribution, yielding 49.2% revenue
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.